scholarly journals Pharmacy and Therapeutics Committee Preparedness Plan for COVID-19

2020 ◽  
Vol 3 (2) ◽  
pp. 55-64 ◽  
Author(s):  
Laila Carolina Abu Esba ◽  
Hana Abdullah Al-Abdulkarim ◽  
Ahmed Alrushidan ◽  
Mohammed Al Harbi
Keyword(s):  
Advisory Committee ◽  
Therapeutic Options ◽  
Healthcare Institution ◽  
Limited Evidence ◽  
Pharmacy And Therapeutics Committee ◽  
Preparedness Plan ◽  
Therapeutics Committee

ABSTRACT As the Pharmacy and Therapeutics (P&T) committee acts as an advisory committee on therapeutic options, it is important during pandemics, such as the current Coronavirus disease 2019 pandemic, to quickly search the evidence, be able to select the most appropriate therapies despite the limited evidence, and make appropriate decisions related to which drugs to procure and stock. Potential therapies and recommendations to the P&T committee at a large healthcare institution as means of a preparedness plan are reviewed here.

ASHP Guidelines on the Pharmacy and Therapeutics Committee and the Formulary System

2008 ◽  
Vol 65 (13) ◽  
pp. 1272-1283 ◽  
Author(s):  
Linda S. Tyler ◽  
Sabrina W. Cole ◽  
J. Russell May ◽  
Mirta Millares ◽  
Michael A. Valentino ◽  
...  
Keyword(s):  
Formulary System ◽  
Pharmacy And Therapeutics Committee ◽  
Therapeutics Committee

Role of the hospital pharmacy and therapeutics committee in detecting and regulating off-label drug use, reply to letter

2011 ◽  
Vol 33 (5) ◽  
pp. 722-723 ◽  
Author(s):  
Esther Duran-Garcia ◽  
Bernardo Santos-Ramos ◽  
Francesc Puigventós-Latorre ◽  
Ana Ortega
Keyword(s):  
Drug Use ◽  
Hospital Pharmacy ◽  
Pharmacy And Therapeutics Committee ◽  
Off Label ◽  
Therapeutics Committee

Management of Motor Symptoms in Multiple Sclerosis

2013 ◽  
Vol 8 (2) ◽  
pp. 124
Author(s):  
Pedro Barros ◽  
Maria José Sá ◽  
◽  
◽  
◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Drug Treatment ◽  
Therapeutic Options ◽  
Current Evidence ◽  
Motor Symptoms ◽  
Limited Evidence ◽  
Significant Development ◽  
Gait Impairment ◽  
Wide Range ◽  
Disease Modifying

Although there has been a significant development, in recent years, regarding disease modifying treatments (DMT) in multiple sclerosis (MS), there is a continuous need to manage the wide range of symptoms associated with MS. Although surveys vary in their results, mobility is a major concern in MS patients. However, limited evidence exists for symptomatic drug treatment and so it is important to consider all therapeutic options in these patients. Here we review the current evidence in the management of three of the most common and disabling motor symptoms: spasticity, tremor and gait impairment.

Sign in / Sign up

Export Citation Format

Share Document